Laura Keita

Sep 20, 2024 | cellandgene.com | Laura Keita |Philip Ross |Antony Hitchcock |AGH Bioconsulting

Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery. Better Audits, Faster Through Transparency And EfficiencyClinical trial audits are evolving.

Sep 19, 2024 | clinicalleader.com | Laura Keita |Dan Schell

Oncology continues to lead priority in global drug development. 44% of all Phase I-III trials are tackling oncology. But as the push to combat cancer evolves, so too has the drug development arena. Don’t miss the next Clinical Leader Solutions Expo spotlighting Early Phase Oncology CROs. Live presentations will highlight the key differentiators of each CRO in an interactive forum built for teams no matter where they are in their partner search.

Aug 18, 2024 | clinicalleader.com | Laura Keita

By Laura (Loa) Keita The clinical trial industry has made significant strides in data management, transitioning from paper-based to electronic systems. However, the audit process, a crucial component of quality assurance, has remained largely unchanged. Traditional audits, characterized by rigid timelines and limited access to documentation, often hinder efficiency and thoroughness.